Browse drugs

…ys prior to treatment with three tail vein injections of 18×106 GPC3 CAR-iNKT cells (50% CAR+) or untransduced iNKT cells on days 3,…

…K, Ross RW, Jacobus S, et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretr…

… without compromising selectivity. Furthermore, the addition of OKT3 alone without allogeneic feeders to the NeoExpand cultures usin…

…estimulation with anti-CD3/CD28 beads and culture with IL-7 and IL-15 for 7 days. To assess anti-tumor function and plasticity, ex vi…

…c therapy, and 44% of patients with epithelial cancer had prior oxaliplatin or irinotecan exposure. Minimally invasive resection was perfor…

…cancers. Primary expansion of TIL from tumors was obtained with IL-2, followed by a standard bulk rapid expansion protocol (bulkREP)…

…=33 non-small cell lung cancer and n=2 small cell) treated with Pembrolizumab, Nivolumab or Durvalumab, either alone or in conjunction with c…

…stman H, Gill AJ, et al. Retrospective evaluation of the use of pembrolizumab in malignant mesothelioma in a real-world Australian population…

…) or unknown (30.8%, 53.8%). The most common ICI agent used was pembrolizumab (92.3%), with 7 patients receiving ICI as a first-line systemic…

…ock IFN and PRR signaling through 3-week ex vivo treatment with Ruxolitinib and Cmpd1,6 inhibitors of JAK1/2 (downstream of IFN) and TBK1(d…

…act as major negative regulators of anti-viral immune response. IFN-I also play a central role in the regulation of anti-tumor immune…

…Chevreau C, Penel N, Bertucci F, Toulmonde M, Bellera C, et al. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a ph…